BCYC
Price
$7.40
Change
-$0.14 (-1.86%)
Updated
Sep 26 closing price
Capitalization
512.87M
31 days until earnings call
RGNX
Price
$9.65
Change
+$0.29 (+3.10%)
Updated
Sep 26 closing price
Capitalization
487.46M
37 days until earnings call
Interact to see
Advertisement

BCYC vs RGNX

Header iconBCYC vs RGNX Comparison
Open Charts BCYC vs RGNXBanner chart's image
Bicycle Therapeutics
Price$7.40
Change-$0.14 (-1.86%)
Volume$126.43K
Capitalization512.87M
REGENXBIO
Price$9.65
Change+$0.29 (+3.10%)
Volume$488.96K
Capitalization487.46M
BCYC vs RGNX Comparison Chart in %
Loading...
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCYC vs. RGNX commentary
Sep 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCYC is a Buy and RGNX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 29, 2025
Stock price -- (BCYC: $7.40 vs. RGNX: $9.65)
Brand notoriety: BCYC and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCYC: 49% vs. RGNX: 83%
Market capitalization -- BCYC: $512.87M vs. RGNX: $487.46M
BCYC [@Biotechnology] is valued at $512.87M. RGNX’s [@Biotechnology] market capitalization is $487.46M. The market cap for tickers in the [@Biotechnology] industry ranges from $98.9B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCYC’s FA Score shows that 1 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • BCYC’s FA Score: 1 green, 4 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, RGNX is a better buy in the long-term than BCYC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCYC’s TA Score shows that 3 TA indicator(s) are bullish while RGNX’s TA Score has 5 bullish TA indicator(s).

  • BCYC’s TA Score: 3 bullish, 5 bearish.
  • RGNX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, RGNX is a better buy in the short-term than BCYC.

Price Growth

BCYC (@Biotechnology) experienced а +6.78% price change this week, while RGNX (@Biotechnology) price change was +8.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.96%. For the same industry, the average monthly price growth was +9.24%, and the average quarterly price growth was +51.43%.

Reported Earning Dates

BCYC is expected to report earnings on Oct 30, 2025.

RGNX is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+3.96% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCYC($513M) has a higher market cap than RGNX($487M). RGNX YTD gains are higher at: 24.838 vs. BCYC (-47.143). RGNX has higher annual earnings (EBITDA): -129.93M vs. BCYC (-240.81M). BCYC has more cash in the bank: 721M vs. RGNX (323M). BCYC has less debt than RGNX: BCYC (7.2M) vs RGNX (77.7M). RGNX has higher revenues than BCYC: RGNX (156M) vs BCYC (19.3M).
BCYCRGNXBCYC / RGNX
Capitalization513M487M105%
EBITDA-240.81M-129.93M185%
Gain YTD-47.14324.838-190%
P/E RatioN/AN/A-
Revenue19.3M156M12%
Total Cash721M323M223%
Total Debt7.2M77.7M9%
FUNDAMENTALS RATINGS
BCYC vs RGNX: Fundamental Ratings
BCYC
RGNX
OUTLOOK RATING
1..100
7772
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
69
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
6347
P/E GROWTH RATING
1..100
10020
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCYC's Valuation (18) in the null industry is somewhat better than the same rating for RGNX (69) in the Biotechnology industry. This means that BCYC’s stock grew somewhat faster than RGNX’s over the last 12 months.

BCYC's Profit vs Risk Rating (100) in the null industry is in the same range as RGNX (100) in the Biotechnology industry. This means that BCYC’s stock grew similarly to RGNX’s over the last 12 months.

BCYC's SMR Rating (97) in the null industry is in the same range as RGNX (98) in the Biotechnology industry. This means that BCYC’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's Price Growth Rating (47) in the Biotechnology industry is in the same range as BCYC (63) in the null industry. This means that RGNX’s stock grew similarly to BCYC’s over the last 12 months.

RGNX's P/E Growth Rating (20) in the Biotechnology industry is significantly better than the same rating for BCYC (100) in the null industry. This means that RGNX’s stock grew significantly faster than BCYC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCYCRGNX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
87%
Momentum
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
80%
MACD
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
75%
Advances
ODDS (%)
Bullish Trend 17 days ago
82%
Bullish Trend 26 days ago
77%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 14 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
83%
Aroon
ODDS (%)
Bearish Trend 3 days ago
86%
Bullish Trend 3 days ago
63%
View a ticker or compare two or three
Interact to see
Advertisement
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RRGAX7.380.08
+1.10%
DWS RREEF Global Real Estate Secc A
GOGFX41.900.44
+1.06%
Victory Sycamore Small Company Opp R
GMXRX16.150.17
+1.06%
Nationwide Mid Cap Market Idx R
FGIQX17.280.14
+0.82%
Macquarie Growth and Income R6
LVPSX97.640.72
+0.74%
ProFunds Large Cap Value Svc

BCYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with RPTX. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then RPTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCYC
1D Price
Change %
BCYC100%
-1.86%
RPTX - BCYC
55%
Loosely correlated
+1.20%
XNCR - BCYC
43%
Loosely correlated
+12.00%
RGNX - BCYC
43%
Loosely correlated
+3.10%
OCUL - BCYC
43%
Loosely correlated
+2.37%
ATXS - BCYC
42%
Loosely correlated
+2.10%
More